Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire July 30, 2020

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020

GlobeNewswire July 23, 2020

Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19

GlobeNewswire July 7, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature's Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant

GlobeNewswire May 29, 2020

Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

GlobeNewswire May 27, 2020

Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program

GlobeNewswire May 13, 2020

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

GlobeNewswire April 30, 2020

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020

GlobeNewswire April 22, 2020

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 5, 2020

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020

GlobeNewswire February 28, 2020

Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium

GlobeNewswire February 19, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology's Genitourinary Cancers Symposium

GlobeNewswire February 13, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum

GlobeNewswire February 1, 2020

Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 8, 2019

Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 7, 2019

Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

GlobeNewswire November 5, 2019

Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019

GlobeNewswire November 4, 2019

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire October 29, 2019

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019

GlobeNewswire October 17, 2019

Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 3, 2019